In an active-control trial with a new treatment and a comparator that has placebo-controlled trials, how might the effect of the new therapy versus placebo be estimated? For many diseases it is not ethically justified to use a placebo-control trial, yet in the United States regulatory efficacy is conceptually defined in comparison with placebo.
superior efficacy of an investigational drug over the current reference therapy, one possible true measure of the efficacy of a new agent is how it would perform in comparison with placebo. The issue addressed in this article is the problem posed by two conflicting situations: (1) efficacy is to be judged against a placebo-control and (2) a placebo-control is considered unethical. It must also be understood that in many countries, including the United States and a number of other countries, a new compound must have an "adequate" risk/benefit ratio to receive regulatory approval; the meaning of "adequate" must be interpreted to some extent in light of other approved therapies.
In many therapeutic areas even approved drugs may have failed to show efficacy (not only statistically, but even as a point estimate of treatment effect) in some placebo-controlled trials. This complicates matters. Another issue is the level of evidence needed for regulatory approval. Simplifying the situation in the United States, regulatory approval often requires either two positive placebo-controlled trials, each with a 2-sided P value <.05, or one positive placebo-controlled trial with a P value <.00125. 2 Still it is possible that a single trial of a In the last 20 years great progress has been made in developing effective drugs, biologics, and devices. Because cardiology has shared in these advances, there are a number of indications with serious, irreversible outcomes where placebo-controlled trials are no longer ethical. One such example is the use of antiplatelet agents for the secondary prevention of vascular ischemic events, where there is convincing evidence from individual studies, as well as the Antiplatelet Trialists' Collaboration (APTC) systematic review, that aspirin reduces the combined risk of stroke, myocardial infarction, or vascular death. 1 Although active-control trials may demonstrate the new agent versus an excellent active-control could provide important information in addition to the relative efficacy of the two compounds. The trial might make it possible to surmise, with reasonable confidence, that the new agent was efficacious at the two-trial paradigm level of scientific evidence, if a placebo arm had been included in the trial. How can we provide reasonable evidence that a new compound evaluated in an active-control setting would have been better than placebo? One solution is to use historic or other data for the active-control versus placebo in combination with data from the activecontrol study.
Method
The method used is a natural extension of a method called the Peto method, 1,3 already used in many meta-analyses; in meta-analyses of randomized trials it was presented by Bucher et al. 4 Because the method uses historic control data from the active-control versus placebo trial(s), in many, perhaps most, instances it will not be possible to obtain complete data sets to pool data for statistical models such as the proportional hazards or Cox model for time to an event. Typically, metaanalyses use a much simpler summary of the data: the number of events in each treatment arm of the trial(s). By assuming no treatment effect and by using both the total number of events and the number of subjects in each treatment arm, it is possible to calculate the expected number of events in each group and the estimated variance or, equivalently, SD of this estimate. The Appendix briefly gives these and the following mathematical details.
With the data given by a 2 × 2 table, one natural summary of the treatment effect is the odds ratio. This ratio gives the betting odds for the occurrence of an outcome event, comparing one therapy with another. 5 The odds ratio is sometimes called the cross-product ratio because of the way it is computed from the 2 × 2 table.   Event?  Treatment arm  Yes  No  Treatment A  a  b  Treatment B  c  d The odds ratio (OR) of an event with treatment A compared with treatment B is equal to
Suppose that a trial of a new agent versus an active-control had actually had a third (placebo) arm and the data for the three arms are:
In this case it follows that the OR of the new compound versus placebo is the product of two terms: (1) the OR of the new compound versus the active-control and (2) the OR of the active-control versus placebo.
Because the natural logarithm of a product is the sum of the natural logarithms of the two ORs, it is possible to estimate the natural log of a new compound versus placebo OR from the product of (1) the OR from the active-control study and (2) the OR from a separate study of the active-control versus placebo. The natural log of the product would be the sum of estimates from two separate studies, and because the results of two separate studies are statistically independent the variance for the sum of the natural logs is equal to the sum of the variances of the two natural logs (details in the Appendix).
It is clear that a major assumption is made here. It is assumed that the data for the active-control versus placebo estimate the same OR as that that would have occurred in the active-control study, had a concurrent placebo arm been included. Because the active-control will usually have been established earlier, the data for the active-control versus placebo is historic. Thus, implicitly, a historic control is used. Also, if the populations of the current study and the prior active-control versus placebo study are not very similar, doubt would rightly be cast on the assumption. The reason for using the OR rather than an absolute effect is that experience has shown that the OR for a treatment effect is much more similar in different study designs, populations, and lengths of follow-up than use of absolute effects. 5 We now consider an example where the method is used.
Example
The CAPRIE study 6 examined the efficacy and safety of clopidogrel (Plavix/Iscover), a new platelet ADP receptor antagonist, in reducing the long-term risk of vascular ischemic events in high-risk patients. A placebo-control was considered unethical in view of the proved effectiveness of aspirin in this clinical setting. There is an extensive history of aspirin versus placebo-controlled trials; these have been published as part of a meta-analysis of antiplatelet agents by the Antiplatelet Trialists' Collaboration. 1 The study therefore used aspirin as an active-control. The CAPRIE trial enrolled 19,185 patients with atherosclerotic arterial disease manifested by recent stroke, recent myocardial infarction, or symptomatic atherosclerotic peripheral vascular disease. Primary analysis of efficacy was based on the first occurrence of ischemic stroke, myocardial infarction, or other vascular death (excluding hemorrhage).
This trial reported a statistically significant result favoring clopidogrel over aspirin (P = .043), with annual rates for the first occurrence of the event cluster of 5.32% and 5.83%, respectively. This provided a relative risk reduction of 8.7% in favor of clopidogrel, with a 95% confidence interval of 0.3% to 16.5%.
How would clopidogrel have performed if there had been a placebo arm present? The Antiplatelet Trialists' Collaboration did not separate ischemic stroke from the stroke data. Thus the outcome cluster used in this example consists of any stroke, myocardial infarction, or vascular death (including hemorrhage). This composite outcome cluster using all stroke is at least as important as using ischemic stroke alone. With use of data from CAPRIE, the resulting point estimate of the OR for clopidogrel versus aspirin is 0.90 (95% CI 0.82-0.99), P = .031. The aspirin/placebo meta-analysis studies categorized under prior myocardial infarction, acute myocardial infarction, prior stroke/transient ischemic attack, and intermittent claudication were very homogeneous with respect to the estimated ORs; the P value testing for heterogeneity was almost equal to 1. For this reason, all the placebo-controlled aspirin trials in the meta-analysis categories mentioned above were included in the comparison. The estimated ORs and the 95% confidence intervals for aspirin versus placebo were 0.78 (0.74-0.82), P = 1.2 × 10 -25 . When the two sources of data are combined, the "synthesized" OR for clopidogrel versus placebo is the product 0.904 × 0.780 = 0.705, rounded to 0.70, with a 95% confidence interval of 0.64 to 0.78. An OR of 0.70 represents a reduction in the OR of approximately 30%. The P value for clopidogrel versus placebo in this comparison is 3.2 × 10 -11 .
Data from the APTC meta-analysis allowed a comparison of three other outcomes. These were (1) stroke, myocardial infarction, or all-cause mortality, (2) all-cause mortality, and (3) vascular mortality. Figure 1 presents the results graphically with the point estimates and 95% confidence intervals.
Sample size
When the historic placebo-controlled trials are known, it is possible to compute the sample size to obtain a given level of statistical significance with a prespecified statistical power for the constructed comparison of the new therapy versus placebo. The formula for this is given in the Appendix. If CAPRIE had been designed with this in mind, one might have argued for statistical significance at the .00125 level. A significance level of .00125 is the significance level equivalent to two independent trials exactly meeting the traditional .05 significance level. However, because the historic aspirin/placebo data involve assumptions, it may be prudent to include an even smaller significance level to obtain a more robust finding. With use of a power of 90% and a significance level of .000125 (10 times less than .00125) the approximate sample size for the entire study would be 5772.
Random effect models
The method of this study assumes that all the trials of the historic control data have the same true OR. This is called a fixed effect model. In some instances it is observed empirically that the ORs of the studies differ more than expected by chance. Statistically this is often dealt with by modeling the variability between the different studies. DerSimonian and Laird 7 give such a method for meta-analyzing clinical trials. Under many circumstances the method has much to recommend it. Biologically one would expect different populations to have at least slightly different treatment effects. Why not always model this possible variability?
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Figure 1
ORs and 95% confidence intervals for clopidogrel versus aspirin (CAPRIE), aspirin versus placebo (APTC meta-analysis), and estimated clopidogrel versus placebo for four outcome clusters.
There are a number of reasons to prefer fixed effects models in meta-analyses of clinical trials.
1. If heterogeneity of treatment effect is considered a large concern, then a drug should never be approved on the basis of only one trial, no matter how large and convincing the treatment effect in the one trial. This is because with only one trial one cannot even estimate the variability between possible trials. Conceptually it could be true that the variability is so large that the true mean effect across possible trials might even be adverse. This would seem to imply that it is ethical, even mandatory, to replicate trials of serious, irreversible end points even with a very beneficial estimated treatment effect and an exceedingly low P value. 2. Perhaps in most areas of human biology drug effects might differ between populations (and thus in trials in different populations). However, the drug effect is usually either beneficial in the different populations or adverse in all the different populations. In statistical terminology the treatment interaction is quantitative and not qualitative. It is not usually important then to know the details of the variability between the different studies. 3. The random effects approach can result in two statistically significant positive trials, but the estimated between-study variability is such that we cannot rule out a fairly substantial possibility of a true negative effect in a future trial. Thus the usual FDA paradigm for drug approval would be satisfied, but such approval might be considered inappropriate from the perspective of the random effects model. 4. If multiple trials exist then one can statistically test for heterogeneity of treatment effect. Although the statistical power of such tests is limited if the heterogeneity is demonstrated, one can then address the between-study variability. 5. In a large number of areas, trials in a meta-analysis have a very uniform treatment effect when the OR or relative risk is used as the summary measure. 6. Individual studies may have very different sites and types of patients and thus there may be considerable possible heterogeneity investigated even within one study. Thus one study may contain a spread of patient populations allowing investigation in different subsets of patients; the need for multiple studies is alleviated. Perhaps one could argue for a random effects approach by clinic. However, the degrees of freedom lost if there are a very large number of clinical sites each with few patients can have an adverse effect. In that case one might prespecify analyses by geographic region, for example. However, when there is heterogeneity within clinical sites usually one looks at main effects; this is equivalent in spirit to the approach advocated here.
Although there is no clear mandate for either approach, we suggest fixed effects models unless the data or strong biologic considerations suggest otherwise. In practice the two approaches will usually give the same result when the heterogeneity is not statistically significant; however, for the reasons advanced above we suggest using the fixed effects approach unless there is moderate evidence that there is a qualitative interaction for the treatment effect.
In addition to the fixed and random effects models mentioned above, enoxaparin was considered and approved by the FDA Cardiovascular and Renal Drugs Advisory Committee on June 26, 1997. Lovenox (enoxaparin) plus heparin and aspirin was compared with heparin plus aspirin in the Efficacy Safety Subcutaneous Exoxaparin in Non-Q-Wave Coronary Events (ESSENCE) trial. The issue of a putative placebo (on a background of aspirin) arose and Durrleman used a Bayesian approach that was later published. 8 Recently the same committee (with many different members) that recommended approval of clopidogrel and enoxaparin considered Refludan (lepirudin) at the May 2, 2000, meeting. At this meeting several FDA statisticians expressed concern about the assumptions inherent in using the historic randomized clinical trials for the active control. They voiced concern that the treatment effect in current trials might be much less than in the prior trials. In large part due to such concerns, Refludan had a mixed vote (favorable with the members present voting and negative when votes were cast by members who had previously left the meeting and not heard all of the deliberations).
Discussion
The method described in this article is a simple, natural extension of methods used for meta-analyses. It does not replace the value of placebo-controlled studies; one of the authors (L. F.) has suggested, only partially facetiously, that "if a placebo is ethical, it is unethical not to use a placebo." 9 However, in the field of cardiovascular medicine, there are many well-established effective drugs for indications with serious, irreversible outcomes. Therefore, to estimate how a new drug might have performed against a placebo, extension from an active-control study is the only choice available. Such extensions are less robust than the use of a concurrent control. The placebo-controlled data are historic in nature, and medical and interventional therapies present a constantly changing background. Populations in different studies are usually not the same. In some areas of investigation, such as psychotropic drugs, individual studies often show no drug effect for reasons never understood. 10 Therefore, in addition to any statistical uncertainty arising from the variability of estimates in the two types of studies used (the active-control trial and the active-control versus placebo study or studies), there is the uncertainty associated with the use of the historic active-control/placebo data and different populations. This uncertainty is not generally amenable to estimation, so scientific judgment, expertise, and experience must play a role. This means that the endeavor is more likely to meet with differences of opinion in the different regulatory and clinical settings about the validity of the results; these cannot be resolved by the usual rules of proof.
The example used in this article is an effective solution for this situation. Clopidogrel was statistically significantly better than the aspirin active-control, and there was a very large database of randomized, doubleblinded, parallel group trials of aspirin versus placebo with the same types of patients. Furthermore, data from the latter trials provide evidence for the uniformity of the aspirin effect across indications and trials. This makes population differences of less concern. Although there is always concern about historic control data, the extreme statistical significance of the "synthetic" clopidogrel versus placebo OR provides very convincing evidence that clopidogrel is much better than placebo for the cluster of outcomes analyzed above, with an odds reduction estimated to be approximately 30%. This value compares favorably with the odds reductions for major outcome events seen with placebo comparisons of other well-accepted cardiovascular treatments, such as angiotensin-converting enzyme inhibitors and β-blockers. [11] [12] [13] [14] Given recent agency concerns, it is imperative that the scientific and regulatory communities have some meeting of the minds so that drug development can rationally proceed in the future. In view of the growing number of effective treatments in all areas of medicine, the method presented here may be useful in overcoming the absence of concurrent placebo comparisons.
One two-armed trial. A standard method, called the Peto method 1 used in meta-analyses and elsewhere for use with one or more 2 × 2 tables involves the use of the observed and expected number of follow-up events and the variance for this difference (under the null hypothesis). 2 The method is biased for very large or equivalently very small ORs. 3 The expected number of events and the variance of the expected number of events is computed by use of the hypergeometric distribution conditionally on the margins of a 2 × 2 table:
The expected number of events in the n 11 cell is equal to ᎏ n 1 n .n .. A test for an OR equal to 1, or equivalently E(n 11 ) = ᎏ n 1 n .n ..
is given by the chi-square test with 1 degree of freedom:
An estimate of the OR is ᎏ c s ᎏ , which is the first step of the Newton-Raphson maximum likelihood estimation of the log ( observed -expected) 2 
ᎏᎏᎏ variance
Fisher, Gent, and Büller 30 n 11 n 12 n 1 . n 21 n 22 n 2 . n. 1 n. 2 n.. A test of the assumed common β = 1 is given by comparing the sum of the observed minus expected number of events to the variance under the null hypothesis. That is, let
Then, under the null hypothesis A test for the homogeneity of the odds ratio across trials is given by
where 0/0 is defined to be Note that
It is important to note that to obtain an appropriate estimate of the OR of the new treatment versus placebo that the activecontrol and placebo OR must be the same as if they were included in the active-control study. One only needs appropriate estimates for the two ORs. Thus to estimate 1ne β N to P we can work with 1n(e β N to A ϫ e β A to P ) = 1ne β N to A + 1ne β A to P = β N to A + β A to P . From the two separate (statistically independent) sets of data-the active-control study and the trial(s) of the activecontrol versus placebo-we can obtain s N to A and c N to A as well as s A to P and c A to P . The estimate of β N to A + β A to P is equal to Sample size for active control studies. Because the activecontrol data are usually known when the active-control study is planned, the sample size for the active-control study may be chosen to obtain specified power against the historic activecontrol versus placebo data as well as to have adequate power for the equivalence-superiority against the active-control. In that case, the larger of the desired sample sizes may be used or if one wants adequate power to ensure, that both ends are obtained, more complex methods (or a conservative Bonferroni correction to the power for each sample size calculation) may be used. Here we deal with the active-control sample size computation. It is assumed that the results are sufficiently homogenous that the fixed-effect size methods of this study are appropriate. In that case the parameters (as defined above) for the active-control/placebo are known: s A to P and c A to P .
Suppose that the probabilities of events under an alternative hypothesis are p N and p A with the 2 × 2 table arranged as follows. The proportion of cases to be randomized to the new therapy is r, a number between 0 and 1 (but not 0 or 1). n 11 = n. 1 (1 -p N ) n. 2 (1 -p A ) n. 1 n. 2 n..
From this the sample size may be computed. Here we derive the formula for equal sample sizes, n/2, in each of the two treatment arms. The true natural log OR and an estimate of the variance of the sample estimate 4 ᎏ )
The lefthand side of the inside of the probability is approximately a standard normal, N(0,1) variable. Thus we need to equate the righthand side of the inequality to z 1 -β . Equating these and using algebraic manipulation and squaring the resulting equation, the sample size is found to satisfy the following quadratic equation for ͙n ෆ: nA + ͙n ෆB + C = 0. Let 
